Our top pick for
IGM Biosciences Inc is a biotechnology business based in the US. IGM Biosciences shares (IGMS) are listed on the NASDAQ and all prices are listed in US Dollars. IGM Biosciences employs 144 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$50.96|
|52-week range||$42.00 - $127.11|
|50-day moving average||$65.94|
|200-day moving average||$73.45|
|Wall St. target price||$103.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.58|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||-5.79%|
|1 month (2021-09-24)||-29.56%|
|3 months (2021-07-26)||-38.05%|
|6 months (2021-04-26)||-24.26%|
|1 year (2020-10-26)||-13.82%|
|2 years (2019-10-25)||121.28%|
|3 years (2018-10-22)||N/A|
|5 years (2016-10-22)||N/A|
|Gross profit TTM||$-39,161,000|
|Return on assets TTM||-24.96%|
|Return on equity TTM||-43.54%|
|Market capitalisation||$1.7 billion|
TTM: trailing 12 months
There are currently 3.2 million IGM Biosciences shares held short by investors – that's known as IGM Biosciences's "short interest". This figure is 1% down from 3.2 million last month.
There are a few different ways that this level of interest in shorting IGM Biosciences shares can be evaluated.
IGM Biosciences's "short interest ratio" (SIR) is the quantity of IGM Biosciences shares currently shorted divided by the average quantity of IGM Biosciences shares traded daily (recently around 124525.70866142). IGM Biosciences's SIR currently stands at 25.4. In other words for every 100,000 IGM Biosciences shares traded daily on the market, roughly 25400 shares are currently held short.
However IGM Biosciences's short interest can also be evaluated against the total number of IGM Biosciences shares, or, against the total number of tradable IGM Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IGM Biosciences's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 IGM Biosciences shares in existence, roughly 100 shares are currently held short) or 0.394% of the tradable shares (for every 100,000 tradable IGM Biosciences shares, roughly 394 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against IGM Biosciences.
Find out more about how you can short IGM Biosciences stock.
We're not expecting IGM Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, IGM Biosciences's shares have ranged in value from as little as $42 up to $127.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IGM Biosciences's is -1.0478. This would suggest that IGM Biosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, IGM Biosciences has bucked the trend.
IGM Biosciences, Inc. , a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. It has a strategic research and license agreement with AbCellera to discover and develop IgM antibodies; and license agreement with AvantGen Inc. for various antibodies against the SARS-CoV-2 virus. The company was formerly known as Palingen, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.